Paradigm Biopharmaceuticals Ltd.
0.15
EUR
0.00
(0.00%)
ISIN
AU000000PAR5
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Paul John Rennie
- Full Time Employees
- 12
- Sector
- Health technology
- Industry
- Pharmaceuticals: generic
- Address
- 500 Collins Street Melbourne VIC Australia 3000
- IPO Date
- Aug 18, 2015
- Website
- paradigmbiopharma.com
- Similar Companies
- Business
- Paradigm Biopharmaceuticals Limited (ASX: PAR) is a clinical stage biopharmaceutical company focused on developing innovative treatments for osteoarthritis and other musculoskeletal disorders. The company advances pentosan polysulfate sodium (PPS), a novel anti-inflammatory and disease-modifying agent administered via subcutaneous injection; its lead product candidate, Zilosul (formerly iPPS), targets knee osteoarthritis through Phase 3 trials including the COMPONENT and FORWARD studies, with additional exploration in back pain, diabetic complications, and mucopolysaccharidosis. Paradigm offers research and development services in drug formulation, clinical trial management, and regulatory submissions, supported by proprietary delivery technologies. [web:previous] Founded in 2014 and headquartered in Melbourne, Australia, Paradigm operates primarily in Australia with clinical trial sites across North America, Europe, and Asia-Pacific, targeting patients with chronic inflammatory conditions and partnering with global contract research organizations. The company serves healthcare providers, pharmaceutical collaborators, and regulatory bodies in the biotechnology sector, emphasizing orphan drug designations for expanded indications. [web:previous] In the past two years, Paradigm has advanced its Phase 3 COMPONENT trial for Zilosul, reporting positive topline data in 2024 demonstrating significant pain reduction and structural improvements in knee osteoarthritis patients; it completed patient enrollment in the FORWARD trial and initiated regulatory discussions with the FDA for potential accelerated approval pathways. Recent strategic moves include a A$30 million capital raise in late 2024 to fund trial completion and manufacturing scale-up, alongside a manufacturing partnership with a leading CDMO for commercial supply readiness. The company expanded its pipeline through preclinical data on PPS for diabetic neuropathy and secured additional intellectual property protections extending exclusivity beyond 2040. [web:previous]